APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vascular Endothelial Growth Factor (VEGF) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Analysis and Forecast 2026-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchVascular Endothelial Growth Factor (VEGF) Inhibitors Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Vascular Endothelial Growth Factor (VEGF) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Vascular Endothelial Growth Factor (VEGF) Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Vascular Endothelial Growth Factor (VEGF) Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Vascular Endothelial Growth Factor (VEGF) Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Vascular Endothelial Growth Factor (VEGF) Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Vascular Endothelial Growth Factor (VEGF) Inhibitors is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Vascular Endothelial Growth Factor (VEGF) Inhibitors include Sanofi., Novartis AG, Bayer AG, Regeneron Pharmaceuticals Inc. and F. Hoffmann-La Roche Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Vascular Endothelial Growth Factor (VEGF) Inhibitors, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Vascular Endothelial Growth Factor (VEGF) Inhibitors, also provides the revenue of main regions and countries. Of the upcoming market potential for Vascular Endothelial Growth Factor (VEGF) Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Vascular Endothelial Growth Factor (VEGF) Inhibitors revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Vascular Endothelial Growth Factor (VEGF) Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Vascular Endothelial Growth Factor (VEGF) Inhibitors revenue, projected growth trends, production technology, application and end-user industry.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Segment by Company

Sanofi.

Novartis AG

Bayer AG

Regeneron Pharmaceuticals Inc.

F. Hoffmann-La Roche Ltd.

Vascular Endothelial Growth Factor (VEGF) Inhibitors Segment by Type

VEGF-D Inhibitor

VEGF-C Inhibitor

VEGF-B Inhibitor

VEGF-A Inhibitor

Vascular Endothelial Growth Factor (VEGF) Inhibitors Segment by Application

Oncology

Ophthalmology

Vascular Endothelial Growth Factor (VEGF) Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vascular Endothelial Growth Factor (VEGF) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vascular Endothelial Growth Factor (VEGF) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vascular Endothelial Growth Factor (VEGF) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Vascular Endothelial Growth Factor (VEGF) Inhibitors in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Vascular Endothelial Growth Factor (VEGF) Inhibitors company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Vascular Endothelial Growth Factor (VEGF) Inhibitors revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. VEGF-D Inhibitor Major Player Table 3. VEGF-C Inhibitor Major Player Table 4. VEGF-B Inhibitor Major Player Table 5. VEGF-A Inhibitor Major Player Table 6. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Oncology Major Player Table 8. Ophthalmology Major Player Table 9. Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Trends Table 10. Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Drivers Table 11. Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Opportunities and Challenges Table 12. Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Restraints Table 13. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Share by Region (2021-2026) Table 16. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Share by Region (2027-2032) Table 18. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Players (2021-2026) Table 20. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Players Headquarters & Area Served Table 22. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Players, Product Type & Application Table 23. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Type (2021-2026) Table 30. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Type (2027-2032) Table 31. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Application (2021-2026) Table 35. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Application (2027-2032) Table 36. Sanofi. Company Information Table 37. Sanofi. Business Overview Table 38. Sanofi. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sanofi. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio Table 40. Sanofi. Recent Development Table 41. Novartis AG Company Information Table 42. Novartis AG Business Overview Table 43. Novartis AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Novartis AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio Table 45. Novartis AG Recent Development Table 46. Bayer AG Company Information Table 47. Bayer AG Business Overview Table 48. Bayer AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Bayer AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio Table 50. Bayer AG Recent Development Table 51. Regeneron Pharmaceuticals Inc. Company Information Table 52. Regeneron Pharmaceuticals Inc. Business Overview Table 53. Regeneron Pharmaceuticals Inc. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Regeneron Pharmaceuticals Inc. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio Table 55. Regeneron Pharmaceuticals Inc. Recent Development Table 56. F. Hoffmann-La Roche Ltd. Company Information Table 57. F. Hoffmann-La Roche Ltd. Business Overview Table 58. F. Hoffmann-La Roche Ltd. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. F. Hoffmann-La Roche Ltd. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio Table 60. F. Hoffmann-La Roche Ltd. Recent Development Table 61. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 62. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 63. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 64. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 65. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 66. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 67. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (US$ Million) & (2027-2032) Table 68. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 69. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 70. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 71. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 72. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 73. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 74. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (US$ Million) & (2027-2032) Table 75. China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 76. China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 77. China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 78. China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 79. Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 80. Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 81. Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 82. Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 83. Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 84. Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Region (US$ Million) & (2021-2026) Table 85. Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Region (US$ Million) & (2027-2032) Table 86. SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2026) & (US$ Million) Table 87. SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2027-2032) & (US$ Million) Table 88. SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2026) & (US$ Million) Table 89. SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2027-2032) & (US$ Million) Table 90. SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 91. SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021-2026) & (US$ Million) Table 92. SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (US$ Million) & (2027-2032) Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Vascular Endothelial Growth Factor (VEGF) Inhibitors Image Figure 2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 4. VEGF-D Inhibitor Image Figure 5. VEGF-C Inhibitor Image Figure 6. VEGF-B Inhibitor Image Figure 7. VEGF-A Inhibitor Image Figure 8. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size Share 2021 VS 2025 VS 2032 Figure 10. Oncology Image Figure 11. Ophthalmology Image Figure 12. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size (US$ Million) & (2021-2032) Figure 13. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Type (2021-2032) Figure 20. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Application (2021-2032) Figure 23. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Type (2021-2032) Figure 25. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Application (2021-2032) Figure 26. North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Country (2021-2032) Figure 27. United States Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Type (2021-2032) Figure 32. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Application (2021-2032) Figure 33. Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Country (2021-2032) Figure 34. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Type (2021-2032) Figure 44. China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Application (2021-2032) Figure 45. Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Type (2021-2032) Figure 47. Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Application (2021-2032) Figure 48. Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Region (2021-2032) Figure 49. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Type (2021-2032) Figure 57. SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Application (2021-2032) Figure 58. SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Country (2021-2032) Figure 59. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • VEGF-D Inhibitor
  • VEGF-C Inhibitor
  • VEGF-B Inhibitor
  • VEGF-A Inhibitor
Applications
  • Oncology
  • Ophthalmology
Companies covered
  • Sanofi.
  • Novartis AG
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market by Type
  3. 1.2.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 VEGF-D Inhibitor
  5. 1.2.3 VEGF-C Inhibitor
  6. 1.2.4 VEGF-B Inhibitor
  7. 1.2.5 VEGF-A Inhibitor
  8. 1.3 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market by Application
  9. 1.3.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Oncology
  11. 1.3.3 Ophthalmology
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Dynamics
  1. 2.1 Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Trends
  2. 2.2 Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Drivers
  3. 2.3 Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Opportunities and Challenges
  4. 2.4 Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Perspective (2021-2032)
  2. 3.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Growth Trends by Region
  3. 3.2.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Region (2021-2026)
  5. 3.2.3 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Players
  2. 4.1.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Players (2021-2026)
  3. 4.1.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Key Players Headquarters & Area Served
  7. 4.4 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Players, Product Type & Application
  8. 4.5 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market CR5 and HHI
  11. 4.6.3 2025 Vascular Endothelial Growth Factor (VEGF) Inhibitors Tier 1, Tier 2, and Tier 3
5 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Type
  1. 5.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2032)
  3. 5.3 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Type (2021-2032)
6 Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Size by Application
  1. 6.1 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2032)
  3. 6.3 Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sanofi.
  2. 7.1.1 Sanofi. Company Information
  3. 7.1.2 Sanofi. Business Overview
  4. 7.1.3 Sanofi. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio
  6. 7.1.5 Sanofi. Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Bayer AG
  14. 7.3.1 Bayer AG Company Information
  15. 7.3.2 Bayer AG Business Overview
  16. 7.3.3 Bayer AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bayer AG Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio
  18. 7.3.5 Bayer AG Recent Developments
  19. 7.4 Regeneron Pharmaceuticals Inc.
  20. 7.4.1 Regeneron Pharmaceuticals Inc. Company Information
  21. 7.4.2 Regeneron Pharmaceuticals Inc. Business Overview
  22. 7.4.3 Regeneron Pharmaceuticals Inc. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Regeneron Pharmaceuticals Inc. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio
  24. 7.4.5 Regeneron Pharmaceuticals Inc. Recent Developments
  25. 7.5 F. Hoffmann-La Roche Ltd.
  26. 7.5.1 F. Hoffmann-La Roche Ltd. Company Information
  27. 7.5.2 F. Hoffmann-La Roche Ltd. Business Overview
  28. 7.5.3 F. Hoffmann-La Roche Ltd. Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue and Gross Margin (2021-2026)
  29. 7.5.4 F. Hoffmann-La Roche Ltd. Vascular Endothelial Growth Factor (VEGF) Inhibitors Product Portfolio
  30. 7.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
8 North America
  1. 8.1 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue (2021-2032)
  2. 8.2 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2032)
  3. 8.2.1 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2026)
  4. 8.2.2 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2027-2032)
  5. 8.3 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Type (2021-2032)
  6. 8.4 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2032)
  7. 8.4.1 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2026)
  8. 8.4.2 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2027-2032)
  9. 8.5 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Application (2021-2032)
  10. 8.6 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country
  11. 8.6.1 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021-2026)
  13. 8.6.3 North America Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue (2021-2032)
  2. 9.2 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2032)
  3. 9.2.1 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2026)
  4. 9.2.2 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2027-2032)
  5. 9.3 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Type (2021-2032)
  6. 9.4 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2032)
  7. 9.4.1 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2026)
  8. 9.4.2 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2027-2032)
  9. 9.5 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Application (2021-2032)
  10. 9.6 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country
  11. 9.6.1 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021-2026)
  13. 9.6.3 Europe Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue (2021-2032)
  2. 10.2 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2032)
  3. 10.2.1 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2026)
  4. 10.2.2 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2027-2032)
  5. 10.3 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Type (2021-2032)
  6. 10.4 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2032)
  7. 10.4.1 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2026)
  8. 10.4.2 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2027-2032)
  9. 10.5 China Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue (2021-2032)
  2. 11.2 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2032)
  3. 11.2.1 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2026)
  4. 11.2.2 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2027-2032)
  5. 11.3 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Type (2021-2032)
  6. 11.4 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2032)
  7. 11.4.1 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2026)
  8. 11.4.2 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2027-2032)
  9. 11.5 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Application (2021-2032)
  10. 11.6 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country
  11. 11.6.1 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021-2026)
  13. 11.6.3 Asia Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue (2021-2032)
  2. 12.2 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Type (2027-2032)
  5. 12.3 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Application (2027-2032)
  9. 12.5 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country
  11. 12.6.1 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Vascular Endothelial Growth Factor (VEGF) Inhibitors Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst